It is a fully human monoclonal antibody that targets human PD-L1, with an IgG1 isotype.

IMC-002 binds to CD47 on the surface of cancer cells, which blocks its interaction with SIRPα. This action induces phagocytosis in macrophages. Furthermore, it enhances the antigen cross-presentation of Dendritic cells (DCs), which activates T-cells. This results in the simultaneous activation of both innate and adaptive immunity. IMC-002 has an optimized affinity that avoids binding to red blood cells (RBCs), providing a superior safety profile compared to competing antibodies.